pp65-specific T cells - Miltenyi Biotec

Drug Profile

pp65-specific T cells - Miltenyi Biotec

Alternative Names: CMV-specific T-cells; IFN-gamma positive selected T-cells

Latest Information Update: 20 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Miltenyi Biotec GmbH; Samsung Medical Center
  • Developer Miltenyi Biotec GmbH
  • Class Cytomegalovirus vaccines; Immunotherapies; Peptide vaccines; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cytomegalovirus infections

Most Recent Events

  • 13 Jan 2015 Preclinical trials in Cytomegalovirus infections treatment in Singapore before January 2015 (IV)
  • 13 Jan 2015 Miltenyi Biotec plans a phase I/II trial for Cytomegalovirus infections in South Korea (NCT02346617)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top